Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jort Vellinga

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Plos One|April 1, 2017
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platformNadine C Salisch, Marija Vujadinovic, Esmeralda van der Helm, et al.
Molecular Immunology|March 20, 2012
Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signalingJens H W Pahl, Dirk H J Verhoeven, Kitty M C Kwappenberg, et al.
Human Gene Therapy|July 17, 2008
Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in miceFrederik H E Schagen, Harm C A Graat, Jan E Carette, et al.
Journal of Virology|March 16, 2004
Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IXJort Vellinga, Martijn J W E Rabelink, Steve J Cramer, et al.
The Journal of Gene Medicine|September 17, 2009
A lentiviral vector-based adenovirus fiber-pseudotyping approach for expedited functional assessment of candidate retargeted fibersTaco G Uil, Jeroen de Vrij, Jort Vellinga, et al.
Vaccine|June 20, 2018
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responsesMarija Vujadinovic, Selina Khan, Koen Oosterhuis, et al.
Nucleic Acids Research|December 9, 2010
Directed adenovirus evolution using engineered mutator viral polymerasesTaco G Uil, Jort Vellinga, Jeroen de Vrij, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Plos One|December 14, 2012
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesRoland Zahn, Gert Gillisen, Anna Roos, et al.
Journal of Thrombosis and Haemostasis : JTH|December 30, 2023
Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccineMarijn van der Neut Kolfschoten, Hanna Inganäs, Clara Perez-Peinado, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Plos One|April 1, 2017
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platformNadine C Salisch, Marija Vujadinovic, Esmeralda van der Helm, et al.
Molecular Immunology|March 20, 2012
Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signalingJens H W Pahl, Dirk H J Verhoeven, Kitty M C Kwappenberg, et al.
Human Gene Therapy|July 17, 2008
Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in miceFrederik H E Schagen, Harm C A Graat, Jan E Carette, et al.
Journal of Virology|March 16, 2004
Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IXJort Vellinga, Martijn J W E Rabelink, Steve J Cramer, et al.
The Journal of Gene Medicine|September 17, 2009
A lentiviral vector-based adenovirus fiber-pseudotyping approach for expedited functional assessment of candidate retargeted fibersTaco G Uil, Jeroen de Vrij, Jort Vellinga, et al.
Vaccine|June 20, 2018
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responsesMarija Vujadinovic, Selina Khan, Koen Oosterhuis, et al.
Nucleic Acids Research|December 9, 2010
Directed adenovirus evolution using engineered mutator viral polymerasesTaco G Uil, Jort Vellinga, Jeroen de Vrij, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Plos One|December 14, 2012
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesRoland Zahn, Gert Gillisen, Anna Roos, et al.
Journal of Thrombosis and Haemostasis : JTH|December 30, 2023
Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccineMarijn van der Neut Kolfschoten, Hanna Inganäs, Clara Perez-Peinado, et al.
Pageof 3